Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts

Drug-Drug Interactions Involving non-CYP Phase I or Phase II Enzymes can we Predict?

Olivier Barberan, Director of Product Development, Aureus Pharma, speaking at ADMET Europe
Date Posted: Thursday, September 16, 2010
Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

Aureus Pharma Announces Participation in EUR 118 Million Biointelligence R&D Programme
The programme is aimed to promote the use of Systemic Modelling and Simulation Tools In The Life Science Industry.
Tuesday, March 23, 2010
Aureus Pharma Extends its Knowledge Database Agreement with Sanofi-Aventis R&D
Aureus will provide new AurSCOPE® knowledge databases and continue to update existing databases for sanofi-aventis' R&D division.
Friday, November 06, 2009
Aureus Pharma to Participate in a European Consortium for Drug Cardiac Toxicity
Aureus’ contribution to the project will be to use its expertise in Ion Channel/hERG knowledge databases to predict the effects of drugs on the heart.
Friday, October 31, 2008
Aureus Pharma Licenses AurWEB to Origenis
AurWEB is designed to allow access to all of Aureus’ knowledge databases, which include AurSCOPE GPCR, Ion Channel, Kinase, ADME/Drug-Drug interactions and hERG.
Thursday, September 07, 2006
Aureus Licenses AurSCOPE ADME/DDI and hERG Knowledge Databases to Siena
Aureus’ ADME/DDI and hERG knowledge databases contain data which can help assess the safety of a potential pharmaceutical candidate.
Thursday, June 08, 2006
Scientific News
Label-Free Binding Analysis Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Vitamin E Keeps Muscles Healthy
Body builders have it right: vitamin E does help build strong muscles, and scientists appear to have figured out one important way it does it.
Microchip Captures Clusters of Circulating Tumor Cells
Researchers have developed a microfluidic chip that can capture rare clusters of circulating tumor cells, which could yield important new insights into how cancer spreads.
New Method For Measuring The Concentration Of Medicines In The Blood
Researchers at EPFL have come up with a quick and portable new device for measuring the amount of medicinal drugs in blood.
Alternate Administration Routes for Psychotropic Drugs Reviewed
A review in the Annals of Pharmacotherapy has examined the literature on alternative routes of administration for antipsychotic and antidepressant medications.
Promising Results of Phase 1/2 Trial of Rociletinib in EGFR Lung Cancer Published
Results have been published of a multi-center phase I/II study of the investigational anti-cancer agent rociletinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC) that had progressed after previous treatment with EGFR inhibitors.
Epilepsy Drug Metabolism Test Launched for Epilepsy and Seizure Disorders
Courtagen Life Sciences, Inc have announced the release of a NGS test focused on detection of anti-epileptic drug (AED) compatibilities and interactions for patients receiving treatment for epilepsy or other seizure disorders.
Supercooling May Aid Drug Delivery
A new study published is the first to break down the rules governing the complex process of crystallization through rapid-cooling.
Quotient Clinical Completes Innovative First-In-Human Program
First-in-human clinical program designed to develop an optimal oral formulation.
Neuropsychiatric Drug Candidate Shows Good Safety & Tolerability
Transition Therapeutics announces results from Phase 1 AME & renal clearance clinical studies of neuropsychiatric drug candidate ELND005.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters